SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab | 1 | N | 1 Adjuvant Arm | 342 | 173 | 0 | 0 | 0 | 0 | 0 | 02/15/2019 | 271 | 104 |
2 Neoadjuvant Pembrolizumab | 172 | 0 | 0 | 0 | 0 | 0 | ||||||||
345 | 0 | 0 | 0 | 0 | 0 | |||||||||
2 | Y | 3 Surgery | 316 | 9 | 0 | 0 | 0 | 0 | 02/15/2019 | |||||
316 | 9 | 0 | 0 | 0 | 0 | |||||||||
3 | Y | 4 Post-Surgery Pembro | 267 | 17 | 0 | 0 | 0 | 0 | 02/15/2019 | |||||
267 | 17 | 0 | 0 | 0 | 0 | |||||||||
S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | 1 | Y | 1 Encorafenib/Binimetinib/Nivolu | 35 | 13 | 8 | 2 | 1 | 0 | 0 | 01/06/2021 | 122 | 47 | |
2 Ipilimumab + Nivolumab | 15 | 9 | 3 | 1 | 0 | 0 | ||||||||
28 | 17 | 5 | 2 | 0 | 0 | |||||||||
Yes | EA6141-Melan, Adv, Nivolumab+Ipi ± Sargmostim | 1 | E | Total Registrations | 51 | 5 | 2 | 2 | 2 | 0 | 03/25/2016 | 218 | 87 | |
51 | 5 | 2 | 2 | 2 | 0 | |||||||||
No | S2015-MELAN, Stg I-II, 1cm v 2cm excision margins | 1 | E | Total Registrations | 195 | 191 | 145 | 72 | 29 | 7 | 05/12/2022 | 170 | 64 | |
195 | 191 | 145 | 72 | 29 | 7 | |||||||||
A091903-Melan, Resected Mucosal, Adj Nivo +/- Cabo | 0 | E | Total Registrations | 1 | 1 | 0 | 0 | 0 | 0 | 11/01/2022 | 68 | 33 | ||
1 | 1 | 0 | 0 | 0 | 0 | |||||||||
1 | E | Total Registrations | 1 | 1 | 0 | 0 | 0 | 0 | 11/01/2022 | |||||
1 | 1 | 0 | 0 | 0 | 0 | |||||||||
EA6174-Merkel, Adjuvant Pembrolizumab vs Observation | 1 | E | Total Registrations | 53 | 11 | 3 | 2 | 0 | 0 | 05/01/2019 | 299 | 108 | ||
53 | 11 | 3 | 2 | 0 | 0 | |||||||||
EA6192-Melan, Adv, Erly Discont of Antibdy Thrpy | 0 | E | Total Registrations | 7 | 5 | 2 | 0 | 0 | 0 | 09/22/2021 | 124 | 49 | ||
7 | 5 | 2 | 0 | 0 | 0 | |||||||||
1 | E | Total Registrations | 8 | 5 | 2 | 0 | 0 | 0 | 09/22/2021 | |||||
8 | 5 | 2 | 0 | 0 | 0 | |||||||||